New ADHD Drugs, Same Old Problems
<p>The FDA approved two new ADHD drugs this year, and they’re being marketed as shiny new medical advances. It sounds exciting, but are these drugs really new and different?</p>
<p>Azstaryz is a stimulant developed by KemPharm, whose <a href="https://www.biospace.com/article/releases/kempharm-inc-announces-uplisting-to-the-nasdaq-global-select-market/" rel="noopener ugc nofollow" target="_blank">CEO called it</a> “the first truly differentiated ADHD medication in years”, and <a href="https://www.contemporarypediatrics.com/view/fda-approves-non-stimulant-qelbree-to-treat-adhd" rel="noopener ugc nofollow" target="_blank">Qelbree is</a> “the first novel non-stimulant approval in a decade,” developed by Supernus Pharmaceuticals.</p>
<p>Azstaryz, which the company’s <a href="https://kempharm.com/kempharm-announces-u-s-launch-of-innovative-adhd-treatment-azstarys-serdexmethylphenidate-and-dexmethylphenidate-capsules-by-corium-inc/" rel="noopener ugc nofollow" target="_blank">press release</a> calls “a first-of-its-kind treatment” and “a true advance in ADHD medicine” is made up of 30% d-methylphenidate, or d-MPH, currently on the market as Focalin by Novartis (itself a version of methylphenidate, the OG ADHD drug, Ritalin).</p>
<p><a href="https://jessemeadows.medium.com/new-adhd-drugs-same-old-problems-89dc5ede8011"><strong>Website</strong></a></p>